Societal preferences for adjuvant melanoma health states: UK and Australia

Societal preferences for adjuvant melanoma health states: UK and Australia

No studies have measured preference-based utility weights for specific toxicities and outcomes associated with approved and investigational adjuvant treatments for patients with resected high-risk melanoma.A cross-sectional study was conducted in the United Kingdom and Australia to obtain utilities...

Full description

Bibliographic Details
Main Authors:	Middleton, M, Atkins, M, Amos, K, Wang, P, Kotapati, S, Sabater, J, Beusterien, K
Format:	Journal article
Language:	English
Published:	BioMed Central 2017

Similar Items

Societal preferences for adjuvant melanoma health states: UK and Australia
by: Mark R. Middleton, et al.
Published: (2017-10-01)

Societal preference values for advanced melanoma health states in the United Kingdom and Australia.
by: Beusterien, K, et al.
Published: (2009)

Patient and Physician Preferences for Treating Adjuvant Melanoma: A Discrete Choice Experiment
by: Beusterien, K, et al.
Published: (2017)

Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma
by: Hemstock, M, et al.
Published: (2020)

Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma
by: Zhang Y, et al.
Published: (2015-07-01)

308 Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma
by: Dirk Schadendorf, et al.
Published: (2020-11-01)

Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis
by: Kabirraaj Toor, et al.
Published: (2021-01-01)

Patient Preferences for Adjuvant Treatment in Muscle-Invasive Urothelial Carcinoma: A Multi-Country Discrete Choice Experiment
by: King-Concialdi K, et al.
Published: (2023-09-01)

Adjuvant Therapy: Melanoma
by: Diwakar Davar, et al.
Published: (2011-01-01)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
by: Wolfram Samlowski, et al.
Published: (2023-02-01)

Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
by: Beusterien K, et al.
Published: (2021-03-01)

Adjuvant treatments in melanoma
by: Luka Simetić, et al.
Published: (2021-01-01)

Pembrolizumab as adjuvant therapy in melanoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01)

Adjuvant and neoadjuvant therapies in melanoma
by: Teresa Amaral, et al.
Published: (2020-10-01)

Patient preferences for chemotherapies used in breast cancer
by: Beusterien K, et al.
Published: (2012-06-01)

The economic and health burden of stroke among younger adults in Australia from a societal perspective
by: Elise Tan, et al.
Published: (2022-02-01)

Normative uncertainty and societal preferences: the problem with evaluative standards
by: Sietze Kai Kuilman, et al.
Published: (2023-07-01)

Taxonomic bias in biodiversity data and societal preferences
by: Julien Troudet, et al.
Published: (2017-08-01)

Stellenbosch coffee society: Societal and locational preferences
by: Sanette FERREIRA, et al.
Published: (2019-02-01)

Public preference on sharing health data to inform research, health policy and clinical practice in Australia: A stated preference experiment.
by: Richard J Varhol, et al.
Published: (2023-01-01)

Public preference on sharing health data to inform research, health policy and clinical practice in Australia: A stated preference experiment
by: Richard J. Varhol, et al.
Published: (2023-01-01)

What matters most?: evidence-based findings of health dimensions affecting the societal preferences for EQ-5D health states
by: Monica Viegas Andrade, et al.
Published: (2013-01-01)

Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment
by: Kumar J, et al.
Published: (2021-07-01)

Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile
by: Alexandra Ikeguchi, et al.
Published: (2020-07-01)

Correction to: The economic and health burden of stroke among younger adults in Australia from a societal perspective
by: Elise Tan, et al.
Published: (2022-02-01)

Transition in the societal value and governance of water resources in Australia and China
by: Jing Wei, et al.
Published: (2023-06-01)

An update on adjuvant systemic therapies in melanoma
by: Evangeline Samuel, et al.
Published: (2019-11-01)

The impact of societal preferences on national monetary policy outcomes
by: Christoph Steinert
Published: (2016-10-01)

Exploring Societal Preferences for Energy Sufficiency Measures in Switzerland
by: Corinne eMoser, et al.
Published: (2015-09-01)

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
by: Wei Wang, et al.
Published: (2023-03-01)

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
by: Hancock, B, et al.
Published: (2004)

Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project
by: Toni Maria Janke, et al.
Published: (2024-12-01)

Adjuvant therapy of melanoma with interferon: lessons of the past decade
by: Kirkwood John M, et al.
Published: (2008-10-01)

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial
by: Lipplaa, A, et al.
Published: (2018)

Japanese patient preferences regarding intermediate to advanced hepatocellular carcinoma treatments
by: Chiba T, et al.
Published: (2019-04-01)

Adjuvant Therapy in Acral Melanoma: A Systematic Review
by: Zhu Z, et al.
Published: (2024-09-01)

Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study
by: Middleton, M, et al.
Published: (2016)

Adjuvant Proton Beam Radiation Therapy for Sinonasal Mucosal Melanoma
by: Jamie S. K. Takayesu, et al.
Published: (2025-02-01)

Adjuvant and neoadjuvant immunotherapy for acral and mucosal melanoma
by: Takaya Komori, et al.
Published: (2025-01-01)

Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment
by: Supreeda Tambunlertchai, et al.
Published: (2022-09-01)